Madrigal Pharmaceuticals ... (MDGL)
| Bid | 305 |
| Market Cap | 6.76B |
| Revenue (ttm) | 317.38M |
| Net Income (ttm) | -391.59M |
| EPS (ttm) | -21.45 |
| PE Ratio (ttm) | -14.28 |
| Forward PE | 195.64 |
| Analyst | Strong Buy |
| Ask | 325.25 |
| Volume | 179,110 |
| Avg. Volume (20D) | 420,658.7 |
| Open | 317.47 |
| Previous Close | 315.48 |
| Day's Range | 304.50 - 317.47 |
| 52-Week Range | 200.08 - 377.46 |
| Beta | -0.69 |
About MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, ...
Analyst Forecast
According to 10 analyst ratings, the average rating for MDGL stock is "Strong Buy." The 12-month stock price forecast is $431.5, which is an increase of 40.90% from the latest price.
Stock ForecastsEarnings Surprise
2 months ago · seekingalpha.com
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's P...
2 months ago · seekingalpha.com
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger OutlookMadrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash posi...
